12 results on '"Traxler‐Weidenauer, Denise"'
Search Results
2. A CircRNA–miRNA–mRNA Network for Exploring Doxorubicin- and Myocet-Induced Cardiotoxicity in a Translational Porcine Model
- Author
-
Mester-Tonczar, Julia, primary, Einzinger, Patrick, additional, Hasimbegovic, Ena, additional, Kastner, Nina, additional, Schweiger, Victor, additional, Spannbauer, Andreas, additional, Han, Emilie, additional, Müller-Zlabinger, Katrin, additional, Traxler-Weidenauer, Denise, additional, Bergler-Klein, Jutta, additional, Gyöngyösi, Mariann, additional, and Lukovic, Dominika, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Effect of allogeneic adipose tissue derived mesenchymal stromal cell treatment in chronic ischemic heart failure with reduced ejection fraction – The SCIENCE Trial
- Author
-
Qayyum, Abbas Ali, Van Klarenbosch, Bas, Frljak, Sabina, Cerar, Andraz, Poglajen, Gregor, Traxler‐weidenauer, Denise, Nadrowski, Pawel, Paitazoglou, Christina, Vrtovec, Bojan, Bergmann, Martin W., Chamuleau, Steven A.j., Wojakowski, Wojtek, Gyöngyösi, Mariann, Kraaijeveld, Adriaan, Hansen, Kristian Schultz, Vrangbæk, Karsten, Jørgensen, Erik, Helqvist, Steffen, Joshi, Francis Richard, Johansen, Ellen Mønsted, Follin, Bjarke, Juhl, Morten, Højgaard, Lisbeth Drozd, Mathiasen, Anders Bruun, Ekblond, Annette, Haack‐sørensen, Mandana, Kastrup, Jens, Qayyum, Abbas Ali, Van Klarenbosch, Bas, Frljak, Sabina, Cerar, Andraz, Poglajen, Gregor, Traxler‐weidenauer, Denise, Nadrowski, Pawel, Paitazoglou, Christina, Vrtovec, Bojan, Bergmann, Martin W., Chamuleau, Steven A.j., Wojakowski, Wojtek, Gyöngyösi, Mariann, Kraaijeveld, Adriaan, Hansen, Kristian Schultz, Vrangbæk, Karsten, Jørgensen, Erik, Helqvist, Steffen, Joshi, Francis Richard, Johansen, Ellen Mønsted, Follin, Bjarke, Juhl, Morten, Højgaard, Lisbeth Drozd, Mathiasen, Anders Bruun, Ekblond, Annette, Haack‐sørensen, Mandana, and Kastrup, Jens
- Abstract
Background and Aims The aim of the SCIENCE trial was to investigate whether a single treatment with direct intramyocardial injections of adipose tissue derived mesenchymal stromal cells (CSCC_ASCs) was safe and improved cardiac function in patients with chronic ischemic heart failure with reduced ejection fraction (HFrEF). Methods The study was a European multi-centre double-blinded placebo-controlled phase II trial using allogeneic CSCC_ASCs from healthy donors or placebo (2:1 randomization). Main inclusion criteria were NYHA II-III, left ventricular ejection fraction (LVEF) < 45%, and NT-ProBNP levels>300 pg/mL. CSCC_ASCs or placebo (isotonic saline) were injected directly into viable myocardium. Primary endpoint was change in left ventricular end-systolic volume (LVESV) at 6 months follow up measured by echocardiography. Results A total of 133 symptomatic HFrEF patients were included. The treatment was safe without any drug-related severe adverse events or difference in cardiac related adverse events during a 3-years follow-up period. There were no significant differences between the groups during follow up in LVESV (0.3 ± 5.0 ml, P = 0.945), nor in secondary endpoints left ventricular end-diastolic volume (−2.0 ± 6.0 ml, P = 0.736) and LVEF (−1.6 ± 1.0%, P = 0.119). The NYHA classification improved slightly within the first year in both groups without any difference between groups. There were no changes in 6-Minute Walk Test, NT-ProBNP, CRP or quality-of-life the first year in any of the two groups. Conclusion The SCIENCE trial demonstrated safety of intramyocardial allogeneic CSCC_ASC therapy in patients with chronic HFrEF. However, it was not possible to improve the predefined endpoints and induce restoration of cardiac function or clinical symptoms, Aims The aim of the SCIENCE trial was to investigate whether a single treatment with direct intramyocardial injections of adipose tissue-derived mesenchymal stromal cells (CSCC_ASCs) was safe and improved cardiac function in patients with chronic ischaemic heart failure with reduced ejection fraction (HFrEF). Methods and results The study was a European multicentre, double-blind, placebo-controlled phase II trial using allogeneic CSCC_ASCs from healthy donors or placebo (2:1 randomization). Main inclusion criteria were New York Heart Association (NYHA) class II–III, left ventricular ejection fraction (LVEF) <45%, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels >300 pg/ml. CSCC_ASCs or placebo (isotonic saline) were injected directly into viable myocardium. The primary endpoint was change in left ventricular end-systolic volume (LVESV) at 6-month follow-up measured by echocardiography. A total of 133 symptomatic HFrEF patients were included. The treatment was safe without any drug-related severe adverse events or difference in cardiac-related adverse events during a 3-year follow-up period. There were no significant differences between groups during follow-up in LVESV (0.3 ± 5.0 ml, p = 0.945), nor in secondary endpoints of left ventricular end-diastolic volume (−2.0 ± 6.0 ml, p = 0.736) and LVEF (−1.6 ± 1.0%, p = 0.119). The NYHA class improved slightly within the first year in both groups without any difference between groups. There were no changes in 6-min walk test, NT-proBNP, C-reactive protein or quality of life the first year in any groups. Conclusion The SCIENCE trial demonstrated safety of intramyocardial allogeneic CSCC_ASC therapy in patients with chronic HFrEF. However, it was not possible to improve the pre-defined endpoints and induce restoration of cardiac function or clinical symptoms.
- Published
- 2023
4. Selection for Transcateter Versus Surgical Aortic Valve Replacement and Mid-Term Survival: Results of the Autheartvist Study
- Author
-
Auer, Johann, primary, Krotka, Pavla, additional, Reichardt, Berthold, additional, Traxler-Weidenauer, Denise, additional, Wendt, Ralph, additional, Mildner, Michael, additional, Ankersmit, Hendrik Jan, additional, and Graf, Alexandra, additional
- Published
- 2023
- Full Text
- View/download PDF
5. Revisiting Prosthesis Choice in Patients Younger than 50 Years: 10 Years Results of the Autheartvisit Study
- Author
-
Traxler-Weidenauer, Denise, primary, Krotka, Pavla, additional, Reichardt, Berthold, additional, Copic, Dragan, additional, Veraar, Cecilia, additional, Mildner, Michael, additional, Wendt, Ralph, additional, Auer, Johann, additional, Mascherbauer, Julia, additional, Ankersmit, Hendrik J., additional, and Graf, Alexandra, additional
- Published
- 2023
- Full Text
- View/download PDF
6. Identification of Gene Expression Signatures for Phenotype-Specific Drug Targeting of Cardiac Fibrosis.
- Author
-
Lukovic, Dominika, Hasimbegovic, Ena, Winkler, Johannes, Mester-Tonczar, Julia, Müller-Zlabinger, Katrin, Han, Emilie, Spannbauer, Andreas, Traxler-Weidenauer, Denise, Bergler-Klein, Jutta, Pavo, Noemi, Goliasch, Georg, Batkai, Sandor, Thum, Thomas, Zannad, Faiez, and Gyöngyösi, Mariann
- Subjects
HEART fibrosis ,ANGIOTENSIN-receptor blockers ,GENE expression ,TARGETED drug delivery ,CARDIOVASCULAR agents ,ACE inhibitors ,CARDIAC hypertrophy ,GENE expression profiling - Abstract
We have designed translational animal models to investigate cardiac profibrotic gene signatures. Domestic pigs were treated with cardiotoxic drugs (doxorubicin, DOX, n = 5 or Myocet
® , MYO, n = 5) to induce replacement fibrosis via cardiotoxicity. Reactive interstitial fibrosis was triggered by LV pressure overload by artificial isthmus stenosis with stepwise developing myocardial hypertrophy and final fibrosis (Hyper, n = 3) or by LV volume overload in the adverse remodeled LV after myocardial infarction (RemoLV, n = 3). Sham interventions served as controls and healthy animals (Control, n = 3) served as a reference in sequencing study. Myocardial samples from the LV of each group were subjected to RNA sequencing. RNA-seq analysis revealed a clear distinction between the transcriptomes of myocardial fibrosis (MF) models. Cardiotoxic drugs activated the TNF-alpha and adrenergic signaling pathways. Pressure or volume overload led to the activation of FoxO pathway. Significant upregulation of pathway components enabled the identification of potential drug candidates used for the treatment of heart failure, such as ACE inhibitors, ARB, ß-blockers, statins and diuretics specific to the distinct MF models. We identified candidate drugs in the groups of channel blockers, thiostrepton that targets the FOXM1-regulated ACE conversion to ACE2, tyrosine kinases or peroxisome proliferator-activated receptor inhibitors. Our study identified different gene targets involved in the development of distinct preclinical MF protocols enabling tailoring expression signature-based approach for the treatment of MF. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
7. Culprit site extracellular DNA and microvascular obstruction in ST-elevation myocardial infarction
- Author
-
Mangold, Andreas, primary, Ondracek, Anna S, additional, Hofbauer, Thomas M, additional, Scherz, Thomas, additional, Artner, Tyler, additional, Panagiotides, Noel, additional, Beitzke, Dietrich, additional, Ruzicka, Gerhard, additional, Nistler, Sonja, additional, Wohlschläger-Krenn, Evelyne, additional, Winker, Robert, additional, Quehenberger, Peter, additional, Traxler-Weidenauer, Denise, additional, Spannbauer, Andreas, additional, Gyöngyösi, Mariann, additional, Testori, Christoph, additional, and Lang, Irene M, additional
- Published
- 2021
- Full Text
- View/download PDF
8. Culprit site extracellular DNA and microvascular obstruction in ST-elevation myocardial infarction.
- Author
-
Mangold, Andreas, Ondracek, Anna S, Hofbauer, Thomas M, Scherz, Thomas, Artner, Tyler, Panagiotides, Noel, Beitzke, Dietrich, Ruzicka, Gerhard, Nistler, Sonja, Wohlschläger-Krenn, Evelyne, Winker, Robert, Quehenberger, Peter, Traxler-Weidenauer, Denise, Spannbauer, Andreas, Gyöngyösi, Mariann, Testori, Christoph, and Lang, Irene M
- Subjects
ST elevation myocardial infarction ,LEUCOCYTE elastase ,CARDIAC magnetic resonance imaging ,DNA ,PERCUTANEOUS coronary intervention - Abstract
Aims Extracellular chromatin and deoxyribonuclease (DNase) have been identified as important players of thrombosis, inflammation, and homeostasis in a murine model. We previously demonstrated that activated neutrophils release neutrophil extracellular traps (NETs) at the culprit site in ST-elevation myocardial infarction (STEMI), which significantly contribute to extracellular chromatin burden, and are associated with larger infarcts. To understand the correlation between neutrophil activation, extracellular chromatin, and infarct size (IS), we investigated these parameters in a porcine myocardial infarction model, and at different time points and sites in a prospective STEMI trial with cardiac magnetic resonance (CMR) endpoints. Methods and results In a prospective STEMI trial (NCT01777750), 101 STEMI patients were included and blood samples were obtained from first medical contact until 6 months after primary percutaneous coronary intervention (pPCI) including direct sampling from the culprit site. CMR was performed 4 ± 2 days and 6 months after pPCI. Neutrophil counts, markers of extracellular chromatin, and inflammation were measured. Double-stranded deoxyribonucleic acid (dsDNA), citrullinated histone 3, nucleosomes, myeloperoxidase, neutrophil elastase, and interleukin (IL)-6 were significantly increased, while DNase activity was significantly decreased at the culprit site in STEMI patients. High neutrophil counts and dsDNA levels at the culprit site correlated with high microvascular obstruction (MVO) and low ejection fraction (EF). High DNase activity at the culprit site correlated with low MVO and high EF. In correspondence, dsDNA correlated with IS in the porcine myocardial infarction model. In porcine infarcts, neutrophils and extracellular chromatin were detected in congested small arteries corresponding with MVO. Markers of neutrophil activation, extracellular chromatin, DNase activity and CMR measurements correlated with markers of systemic inflammation C-reactive protein and IL-6 in patients. Conclusions NETs and extracellular chromatin are important determinants of MVO in STEMI. Rapid degradation of extracellular chromatin by DNases appears to be crucial for microvascular patency and outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Mechanical Aortic Valve Prostheses Offer a Survival Benefit Over Bioprostheses Among 50 to 65-Year-Olds: The AUTHEARTVISIT Study
- Author
-
Traxler-Weidenauer, Denise, primary, Krotka, Pavla, additional, Laggner, Maria, additional, Mildner, Michael, additional, Graf, Alexandra, additional, Reichardt, Berthold, additional, Auer, Johann, additional, Mascherbauer, Julia, additional, and Ankersmit, Hendrik J., additional
- Published
- 2021
- Full Text
- View/download PDF
10. Multimarker Approach to Identify Patients with Coronary Artery Disease at High Risk for Subsequent Cardiac Adverse Events: The Multi-Biomarker Study
- Author
-
Giurgea, Georgiana-Aura, primary, Zlabinger, Katrin, additional, Gugerell, Alfred, additional, Lukovic, Dominika, additional, Syeda, Bonni, additional, Mandic, Ljubica, additional, Pavo, Noemi, additional, Mester-Tonczar, Julia, additional, Traxler-Weidenauer, Denise, additional, Spannbauer, Andreas, additional, Kastner, Nina, additional, Müller, Claudia, additional, Anvari, Anahit, additional, Bergler-Klein, Jutta, additional, and Gyöngyösi, Mariann, additional
- Published
- 2020
- Full Text
- View/download PDF
11. Topical application of apoptotic peripheral mononuclear blood cell secretome enhances epithelisation in genetically diabetic db/db mice
- Author
-
Traxler-Weidenauer, Denise, Keibl, Claudia, Lidinsky, Dominika, Marsh, Leigh M., Nürnberger, Sylvia, Hartinger, Joachim, Berger, Tanja, Simader, Elisabeth M., Nemec, Lucas, Mildner, Michael, Redl, Heinz, Olschewski, Andrea, Gabriel, Christian, Slezak, Paul, and Ankersmit, Hendrik J.
- Subjects
ddc: 610 ,610 Medical sciences ,Medicine - Abstract
Introduction: A major complication in diabetic patients is foot ulcer. However, to date no sufficient therapy can be offered to those patients. The supernatant of apoptotic peripheral mononuclear blood cells (APOSEC), has previously shown beneficial effects in tissue regeneration and wound healing in[for full text, please go to the a.m. URL], 48. Jahrestagung der Deutschen Gesellschaft der Plastischen, Rekonstruktiven und Ästhetischen Chirurgen (DGPRÄC), 55. Jahrestagung der Österreichischen Gesellschaft für Plastische, Ästhetische und Rekonstruktive Chirurgie, 22. Jahrestagung der Vereinigung der Deutschen Ästhetisch-Plastischen Chirurgen (VDÄPC)
- Published
- 2017
- Full Text
- View/download PDF
12. Effect of allogeneic adipose tissue-derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction - the SCIENCE trial.
- Author
-
Qayyum AA, van Klarenbosch B, Frljak S, Cerar A, Poglajen G, Traxler-Weidenauer D, Nadrowski P, Paitazoglou C, Vrtovec B, Bergmann MW, Chamuleau SAJ, Wojakowski W, Gyöngyösi M, Kraaijeveld A, Hansen KS, Vrangbaek K, Jørgensen E, Helqvist S, Joshi FR, Johansen EM, Follin B, Juhl M, Højgaard LD, Mathiasen AB, Ekblond A, Haack-Sørensen M, and Kastrup J
- Subjects
- Humans, Chronic Disease, Quality of Life, Stroke Volume, Treatment Outcome, Ventricular Function, Left, Double-Blind Method, Heart Failure, Hematopoietic Stem Cell Transplantation, Mesenchymal Stem Cells
- Abstract
Aims: The aim of the SCIENCE trial was to investigate whether a single treatment with direct intramyocardial injections of adipose tissue-derived mesenchymal stromal cells (CSCC_ASCs) was safe and improved cardiac function in patients with chronic ischaemic heart failure with reduced ejection fraction (HFrEF)., Methods and Results: The study was a European multicentre, double-blind, placebo-controlled phase II trial using allogeneic CSCC_ASCs from healthy donors or placebo (2:1 randomization). Main inclusion criteria were New York Heart Association (NYHA) class II-III, left ventricular ejection fraction (LVEF) <45%, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels >300 pg/ml. CSCC_ASCs or placebo (isotonic saline) were injected directly into viable myocardium. The primary endpoint was change in left ventricular end-systolic volume (LVESV) at 6-month follow-up measured by echocardiography. A total of 133 symptomatic HFrEF patients were included. The treatment was safe without any drug-related severe adverse events or difference in cardiac-related adverse events during a 3-year follow-up period. There were no significant differences between groups during follow-up in LVESV (0.3 ± 5.0 ml, p = 0.945), nor in secondary endpoints of left ventricular end-diastolic volume (-2.0 ± 6.0 ml, p = 0.736) and LVEF (-1.6 ± 1.0%, p = 0.119). The NYHA class improved slightly within the first year in both groups without any difference between groups. There were no changes in 6-min walk test, NT-proBNP, C-reactive protein or quality of life the first year in any groups., Conclusion: The SCIENCE trial demonstrated safety of intramyocardial allogeneic CSCC_ASC therapy in patients with chronic HFrEF. However, it was not possible to improve the pre-defined endpoints and induce restoration of cardiac function or clinical symptoms., (© 2023 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.